Sophrosyne Capital’s Altimmune ALT Stock Holding History

Sophrosyne Capital’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-1,667	Closed	-$903K	–	35
2014 Q4	$903K	Hold	1,667	–	–	1.39%	20
2014 Q3	$892K	Buy	+1,667	New	+$872K	1.05%	31
2014 Q2	–	Sell	-608	Closed	-$335K	–	65
2014 Q1	$335K	Sell	608 -39	-6%	-$22.8K	0.29%	52
2013 Q4	$362K	Buy	+647	New	+$386K	0.32%	40
2013 Q3	–	Sell	-2,683	Closed	-$1.28M	–	67
2013 Q2	$1.28M	Buy	+2,683	New	+$1.33M	1%	28

Other funds holding ALT

PGCM

Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OTPPB

Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

GMCM

Gruber & McBaine Capital Management San Francisco, California $369M AUM 12.23% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Sophrosyne Capital's ALT Position: Q1 2015 in Review

Sophrosyne Capital sold out of Altimmune (ALT) in Q1 2015, closing a stake of 1,667 shares — an estimated $903K sold.

Sophrosyne Capital first reported a position in ALT in Q2 2013 and held it in 5 quarters. The position peaked at $1.28M in Q2 2013. 36 funds tracked by Wall St. Rank hold ALT as of Q1 2015.

Sophrosyne Capital reported no remaining Altimmune position as of Q1 2015 after selling out during the quarter.
Sophrosyne Capital sold 1,667 Altimmune shares in Q1 2015, an estimated $903K.
Sophrosyne Capital first reported a position in Altimmune in Q2 2013 and held it in 5 quarters.
Sophrosyne Capital's Altimmune position peaked at $1.28M in Q2 2013.
36 funds tracked by Wall St. Rank held Altimmune as of Q1 2015.

Based on Sophrosyne Capital's 13F filing for Q1 2015, filed 20 Apr 2015.